In the tradition of printed newspapers, most news websites reserve the prime real estate “above the fold” for their biggest headlines. Since late May, however, sites including the Financial Times and the Economist have instead been greeting visitors with a text box warning them that they are being tracked.
The notifications explain to readers that the publications have placed a cookie in their browsers—a bit of code that allows the sites to record what pages they visit. Cookies are hardly unusual: many websites (including Technology Review’s) place a half-dozen in visitors’ machines. What is unusual is that a website would bother to tell anyone. Continue reading Privacy Laws Turn Europe into Economic Laboratory→
Europe’s next elite research centers could be built in the poor regions in the south and east of the continent but managed by prestigious research institutions in, say, the United Kingdom, Germany, or Sweden. That’s one of several ideas now under discussion in the European Parliament to bolster research and innovation in areas where they haven’t thrived, in hopes of accelerating economic development. Continue reading Europe mulls plans to boost research in poorer regions→
Argentina is nationalising its science output, following last month’s nationalisation of energy company YPF. Only this time, the benefits should be international. On 23 May the house of representatives, Argentina’s lower house, approved a bill that would require the results of all scientific research conducted at the Argentina’s National System for Science and Research or by researchers funded by it to be made freely available in an online depository. Continue reading Argentine legislators approve open access law→
A £250-million (US$397-million) investment in venture capital for translational research in the United Kingdom could create jobs. The European Investment Fund in Luxembourg City and Cancer Research Technology (CRT), the commercial arm of the London-based charity Cancer Research UK, are jointly investing £50 million in the development of potential cancer drugs. A separate £200-million initiative by the Wellcome Trust in London will support early-stage biotechnology firms. Keith Blundy, chief executive of CRT, says that experts in drug development should find opportunities as the funding helps to take more drug candidates through to clinical trials.
